Transplant News and Research

RSS

Cord Blood America announces Quality Service Guarantee for stem cell engraft

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced a $50,000 Quality Service Guarantee.

27 Aug 2010

ThermoGenesis files Certificate of Amendment for reverse stock split

ThermoGenesis Corp.,a leading supplier of innovative products and services that process and store adult stem cells, said it has filed a Certificate of Amendment to its Amended and Restated Certification of Incorporation to effect its previously announced one-for-four reverse stock split of its common stock.

27 Aug 2010

China PharmaHub signs distribution agreement for radioactive glass sphere treatment for liver cancer

China PharmaHub Corp. ("PharmaHub"), which has recently merged with World Wide Relics which has changed its name to China PharmaHub Corp, and is in the process of obtaining approval from FINRA to trade under its new name with a new symbol, announced today that it has signed an Exclusive Distribution Agreement ("Agreement") with a world leader in precision glass technology which can be utilized to manufacture high precision radioactive glass spheres that emit alpha, beta or gamma radiation, either individually or in combination, for the treatment of malignant tumors of the liver.

26 Aug 2010

BioTrends Research Group report provides in-depth view of kidney transplantation market

BioTrends Research Group, Inc. recently published its TreatmentTrends: Kidney Transplantation report. This report is based on online survey results from over 150 physicians (general nephrologists, transplant nephrologists and transplant surgeons). It provides an in-depth view of the kidney transplantation market, including the roles of the various specialties, promotional efforts and sales representative messaging, barriers to kidney transplant, the care of post-transplant patients, and current and projected use of immunosuppressive agents for induction, maintenance and acute rejection.

26 Aug 2010

New book on fighting hair loss

World renowned hair loss expert, Dr. Larry Shapiro, announced the release of his new book, Fight Hair Loss and Win! and says that Elin Nordegren is not alone when it comes to hair loss as a result of stress. Shapiro says millions of women and men are experiencing the same and that heightened levels of stress, popular nutritional supplements, hormonal imbalances and many other unsuspecting factors are now linked to hair loss.

26 Aug 2010

Xcellerex, SK Chemicals sign memorandum of understanding to expand vaccine business in Korea

Xcellerex, Inc. announced today that it has signed a memorandum of understanding with SK Chemicals, Co., Ltd., one of South Korea's largest industrial groups, for an alliance to develop and commercialize SK-developed vaccines with Xcellerex's FlexFactory biomanufacturing platform. The companies expect to define specific terms of the alliance in the coming months.

26 Aug 2010

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells. This multicenter Phase I safety trial will enroll a total of 16 long-term, or chronic, spinal cord injury patients, with an American Spinal Injury Association (ASIA) Grade A level of impairment, one-to-two years post-injury.

26 Aug 2010

FibroGen announces study results of recombinant human type III collagen in corneal damage

FibroGen, Inc., today announced results of a 2-year clinical study demonstrating that surgical implantation of biosynthetic corneas formulated with the company's proprietary recombinant human type III collagen (rhCIII) restored vision and promoted nerve regeneration (restoring sensitivity) in patients who had corneal damage and significant vision loss.

26 Aug 2010

TRT receives patent rights for procedure of reattaching damaged soft tissue to bone

Tissue Regeneration Technologies, LLC (TRT), a Woodstock, Georgia medical technology company, recently received the rights to a new patent to bolster its SoftWave technology portfolio. The patent covers a method of reattaching damaged soft tissue to bone.

26 Aug 2010

Gene linked to Fuchs corneal dystrophy discovered

A 13-member research team led by University of Oregon scientist Dr. Albert O. Edwards has found a gene likely responsible for Fuchs corneal dystrophy, an inheritable genetic disorder and leading cause of corneal transplant operations.

26 Aug 2010

HCM patients undergoing transplant can expect reasonable long-term survival rates: Research

Transplant surgery to correct the most common type of genetic heart disease yields similar short-term and potentially greater long-term survival rates as transplant surgery for other heart diseases, according to research reported in Circulation: Heart Failure, an American Heart Association journal.

25 Aug 2010

3Sbio, Isotechnika Pharma sign development and commercialization agreement for voclosporin inhibitor

Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, and 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the signing of a development and commercialization agreement for voclosporin, a next generation calcineurin inhibitor being developed for use in the prevention of organ rejection following transplantation and the treatment of autoimmune diseases.

25 Aug 2010

Surgeons use Twitter to document first double hand transplant procedure

A team of surgeons from Kleinert Kutz and Associates and the University of Louisville are preparing to perform yet another hand transplant in the next few hours at the Jewish Hospital Hand Care Center. Surgeons plan to document the surgery, which will be the facility's first double hand transplant, by using Twitter, to provide short, real-time updates as the procedure takes place.

25 Aug 2010

3SBio and Isotechnika enter strategic agreement for voclosporin in China

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products and Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, today announced the signing of a development and commercialization agreement for voclosporin.

24 Aug 2010

Raptor Pharmaceutical updates on cysteamine bitartrate Phase 3 clinical trial in cystinosis patients

Raptor Pharmaceutical Corp.,provides updates on timelines related to its clinical programs including the pivotal Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

24 Aug 2010

USPTO grants Taligen patent for TT30 lead product candidate

Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,759,304, entitled "Targeting Complement Factor H For Treatment of Diseases", covering the composition of matter for its lead product candidate, TT30, a novel fusion protein that selectively binds to complement activated cells to locally regulate the complement system.

24 Aug 2010

Removing corticosteroid regimen after surgery results in better graft survival rates

University of Cincinnati (UC) analysis of 10 years of data from local kidney transplant patients shows that patients removed from a corticosteroid regimen shortly after surgery have better graft survival rates, better survival rates and fewer cardiovascular events than patients kept on the traditional regimen of long-term steroids.

24 Aug 2010

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

23 Aug 2010

Taligen Therapeutics announces closing on $10M tranche of Series B financing

Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that it has closed on a $10 million tranche of a Series B financing, based on substantial progress with the company's product pipeline including advancing the lead product candidate, TT30, toward clinical development.

23 Aug 2010

FDA approves Alexion's Rhode Island manufacturing facility as commercial supply source for Soliris

Alexion Pharmaceuticals, Inc. today announced that the US Food and Drug Administration (FDA) has approved Alexion's Rhode Island manufacturing facility (ARIMF) in Smithfield, Rhode Island as a second source of commercial supply for Soliris® (eculizumab).

23 Aug 2010

Transplant News and Research

Cord Blood America announces Quality Service Guarantee for stem cell engraft

ThermoGenesis files Certificate of Amendment for reverse stock split

China PharmaHub signs distribution agreement for radioactive glass sphere treatment for liver cancer

BioTrends Research Group report provides in-depth view of kidney transplantation market

New book on fighting hair loss

Xcellerex, SK Chemicals sign memorandum of understanding to expand vaccine business in Korea

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

FibroGen announces study results of recombinant human type III collagen in corneal damage

TRT receives patent rights for procedure of reattaching damaged soft tissue to bone

Gene linked to Fuchs corneal dystrophy discovered

HCM patients undergoing transplant can expect reasonable long-term survival rates: Research

3Sbio, Isotechnika Pharma sign development and commercialization agreement for voclosporin inhibitor

Surgeons use Twitter to document first double hand transplant procedure

3SBio and Isotechnika enter strategic agreement for voclosporin in China

Raptor Pharmaceutical updates on cysteamine bitartrate Phase 3 clinical trial in cystinosis patients

USPTO grants Taligen patent for TT30 lead product candidate

Removing corticosteroid regimen after surgery results in better graft survival rates

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Taligen Therapeutics announces closing on $10M tranche of Series B financing

FDA approves Alexion's Rhode Island manufacturing facility as commercial supply source for Soliris

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News